Shots:

• BioAtla to receive $20M upfront- $249M as WW development & regulatory milestones- commercial milestones and royalties in Beigene’s territory (Asia (ex-Japan)- Australia and New Zealand). Beigene to get WW co-exclusive & exclusive development & commercialization rights respectively for BioAtla’ BA3071 in combination with Beigene’s tislelizumab
• Beigene to take care of all development & commercialization cost in Asia (ex-Japan)- Australia and New Zealand- and the companies will jointly share the cost in addition to profit/loss in ROW 
• BA3071 is an investigational CTLA-4 inhibitor will be evaluated in P-I/II as monothx and in combination with Tislelizumab- with its expected onset in H2’19 and IND submission in mid-2019. Tislelizumab (BGB-A317) is an IgG4 anti–PD-1 mAb targeted to minimize binding to FcγR on macrophages

Ref: GlobeNewsWire | Image: Twitter